You are using an outdated browser. Please upgrade your browser to improve your experience.

You are here

Hepatitis C

The PMC reviewed relevant performance measures and makes the following recommendations.

Printable version of the recommendations.
Addendum to printable version of the recommendations.

ACP supports this measure.

ID# QPP/MIPS: 387
Not NQF-endorsed

More Information

Annual Hepatitis C Virus Screening for Patients who are Active Injection Drug Users

Percentage of patients, regardless of age, who are active injection drug users who received screening for HCV infection within the 12 month reporting period.
Date Reviewed: November 19, 2017

ACP supports this measure.

ID# QPP/MIPS: 400
Not NQF-endorsed

More Information

One-Time Screening for Hepatitis C Virus for Patients at Risk

Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis, OR birthdate in the years 1945-1965 who received one-time screening for hepatitis C virus (HCV) infection.
Date Reviewed: November 19, 2017

ACP does not support this measure.

ID# QPP/MIPS: 390
Not NQF-endorsed

More Information

Discussion and Shared Decision Making Surrounding Treatment Options

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C with whom a physician or other qualified healthcare professional reviewed the range of treatment options appropriate to their genotype and demonstrated a shared decision making approach with the patient. To meet the measure, there must be documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment.
Date Reviewed: November 19, 2017

ACP does not support this measure.

ID# QPP/MIPS: 401
Not NQF-endorsed

More Information

Screening for Hepatocellular Carcinoma in Patients with Cirrhosis

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period.
Date Reviewed: November 19, 2017

ACP does not support this measure.

ID# NQF 0393
ID# PQRS 83

More Information

Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C seen for an initial evaluation who had HCV RNA testing ordered or previously performed
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# PQRS 90
[No longer NQF-endorsed]

More Information

Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Treatment

Percentage of female patients aged 18 to 44 years and all men aged 18 years and older with a diagnosis chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of antiviral treatment
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# NQF 0395
ID# PQRS 84

More Information

Hepatitis C Ribonucleic Acid (RNA) Testing Before Initiating Treatment

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment (paired with NQF 0396)
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# NQF 0396
ID# PQRS 85

More Information

HCV Genotype Testing Prior to Treatment

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment (paired with NQF 0395)
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# PQRS 86
[No longer NQF-endorsed]

More Information

Hepatitis C: Antiviral Treatment Prescribed

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed at a minimum peginterferon and ribavirin therapy within the 12 month reporting period
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# NQF 0398
ID# PQRS 87

More Information

Hepatitis C: HCV RNA Testing at No Greater Than Week 12 of Treatment

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at no greater than 12 weeks from initiation of antiviral treatment
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# NQF 0399
ID# PQRS 183

More Information

Hepatitis C: Hepatitis A Vaccination

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A (paired with PQRS 184)
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# PQRS 184
[No longer NQF-endorsed]

More Information

Hepatitis C: Hepatitis B Vaccination

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received at least one injection of hepatitis B vaccine, or who have documented immunity to hepatitis B
Date Reviewed: July 26, 2014

ACP does not support this measure.

ID# PQRS 89
[No longer NQF-endorsed]

More Information

Hepatitis C: Counseling Regarding Risk of Alcohol Consumption

Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled regarding the risks of alcohol consumption at least once within the 12 month reporting period
Date Reviewed: July 26, 2014